Search hospitals > Quebec > MONTREAL
Centre Hospitalier Universitaire Sainte-Justine
Claim this profileMONTREAL, Quebec H3T 1C5
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Brain Tumor
Conducts research for Sarcoma
Conducts research for Lymphoma
468 reported clinical trials
41 medical researchers
Summary
Centre Hospitalier Universitaire Sainte-Justine is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Sarcoma, Lymphoma and other specialties. Centre Hospitalier Universitaire Sainte-Justine is involved with conducting 468 clinical trials across 780 conditions. There are 41 research doctors associated with this hospital, such as Yvan Samson, Monia Marzouki, Jocelyn Gravel, MD, and Colette Deslandres.Area of expertise
1Leukemia
Global LeaderNTRK1 positive
NTRK positive
t(8;21)(q22;q22) positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Yvan SamsonCentre Hospitalier Universitaire Sainte-Justine4 years of reported clinical research
Studies Leukemia
Studies Tumors
35 reported clinical trials
81 drugs studied
Monia MarzoukiCentre Hospitalier Universitaire Sainte-Justine4 years of reported clinical research
Expert in Tumors
Studies Cancer
28 reported clinical trials
73 drugs studied
Jocelyn Gravel, MDCHU Sainte-Justine2 years of reported clinical research
Studies Recurrence
Studies Gastroenteritis
6 reported clinical trials
7 drugs studied
Colette DeslandresCentre Hospitalier Universitaire Sainte-Justine2 years of reported clinical research
Studies Crohn's Disease
Studies Inflammatory Bowel Disease
3 reported clinical trials
2 drugs studied
Clinical Trials running at Centre Hospitalier Universitaire Sainte-Justine
Brain Tumor
Germ Cell Tumors
Osteosarcoma
Langerhans Cell Histiocytosis
Non-Hodgkin's Lymphoma
Rhabdomyosarcoma
Tumors
Rhabdoid Tumor
Medulloblastoma
Cancer
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Selumetinib vs Carboplatin/Vincristine
for Brain Cancer
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.
Recruiting2 awards Phase 328 criteria
Selumetinib + Vinblastine
for Low-Grade Glioma
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth by stopping cell division and may kill cancer cells. Giving selumetinib in combination with vinblastine may work better than selumetinib alone in treating recurrent or progressive low-grade glioma.
Recruiting2 awards Phase 339 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Centre Hospitalier Universitaire Sainte-Justine?
Centre Hospitalier Universitaire Sainte-Justine is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Sarcoma, Lymphoma and other specialties. Centre Hospitalier Universitaire Sainte-Justine is involved with conducting 468 clinical trials across 780 conditions. There are 41 research doctors associated with this hospital, such as Yvan Samson, Monia Marzouki, Jocelyn Gravel, MD, and Colette Deslandres.
Where is Centre Hospitalier Universitaire Sainte-Justine located?
**Centre Hospitalier Universitaire Sainte-Justine**
- **Address:** 3175 Chemin de la Côte-Sainte-Catherine, Montreal, Quebec.
- **Public Transit:** Take the Blue Line metro to Station Édouard-Montpetit, followed by a 15-minute walk to the hospital.
Who should I call to ask about financial aid or insurance network?
For financial assistance or insurance-related inquiries at Centre Hospitalier Universitaire Sainte-Justine, please call the general contact number at 514-345-4931. You may also find additional information on the hospital's website at chusj.org.
What insurance does Centre Hospitalier Universitaire Sainte-Justine accept?
The Centre Hospitalier Universitaire Sainte-Justine (CHUSJ) accepts insurance plans from the Régie de l'assurance maladie du Québec (RAMQ), providing free or low-cost medical care to Quebec residents, including eligible expats. Expats must choose between public or private prescription drug insurance through RAMQ or their employer, as this is not covered by Quebec's universal healthcare. Additionally, CHUSJ offers exclusive benefits on insurance and financial products to its employees through Beneva.
What awards or recognition has Centre Hospitalier Universitaire Sainte-Justine received?
Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine) in Montreal, Quebec, is a premier mother-child research institution affiliated with Université de Montréal. It employs a dedicated team of over 1,200 individuals, including more than 210 researchers and 450 graduate and postgraduate students, focused on translating discoveries into innovative healthcare solutions. CHU Sainte-Justine is recognized by the World Health Organization (WHO) as a "Health Promoting Hospital" and is an integral part of Université de Montréal's network of excellence in health.